NRTIs block an enzyme of the human immunodeficiency virus called reverse transcriptase that allows HIV to infect human cells, particularly CD4 cells or lymphocytes. Reverse transcriptase converts HIV genetic material, which is RNA, into human genetic material, which is DNA. The human-like DNA of HIV then becomes part of the infected person’s own cells, allowing the cell to produce RNA copies of the HIV that can then go on to attack other not yet infected cells. Thus, blocking reverse transcriptase prevents HIV from taking over (infecting) human cells.
There are still tremendous hurdles. Thirty-five million people in the world are living with the virus. In sub-Saharan Africa, where most new cases are reported, sixty-three per cent of those eligible for the drug regimen do not receive it; those who do often fail to receive it in full. In the United States, a year’s worth of HAART costs many thousands of dollars per patient, and the long-term side effects can be debilitating.
There has been a great deal of attention given to the more recently identified problem of “lipodystrophy.” Individuals suffering from this syndrome can be categorized as having lipohypertrophy (fat accumulation) syndromes, such as the “buffalo hump” on the back of the neck, breast enlargement, or increased abdominal girth. Others primarily suffer from lipoatrophy with fat loss under the skin with complaints of prominent veins on the arms and legs, sunken cheeks, and decreased gluteal (buttock) size. These syndromes appear to be related to multiple factors, including, but not limited to, drug therapy. The NRTIs appear to be most closely linked to lipoatrophy, in particular D4T and to a lesser extent ZDV. In fact, some studies have suggested slow accumulation of fat in those who modify the NRTI component of their regimen. Some NRTIs also have been linked to elevation in lipid (fat) levels in the blood. While switching therapy is always a consideration in those experiencing potential drug-related toxicity, this should only be done under the careful supervision of an experienced HIV provider.
© 2004-2018 All rights reserved. MNT is the registered trade mark of Healthline Media. Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.
human T-lymphotropic virus (HTLV) either of two related species of retroviruses that have an affinity for the helper cell type of T lymphocytes. HTLV-1 causes chronic infection and is associated with adult T-cell leukemia and a type of myelopathy. HTLV-2 has been isolated from an atypical variant of hairy cell leukemia and from patients with other hematological disorders, but no clear association with disease has been established.
In 2008, 2,120,000 people were receiving treatment – 30% of the total number needing it. In 2012, this figure had risen to 7.6 million. Because the WHO expanded its criteria for people who would benefit from antiretroviral therapy, this still only equates to 25% of the population who needs it.
iliotibial band syndrome; ITBS; iliotibial band friction syndrome; ITBFS overuse-associated, friction-induced inflammation of ITB and associated bursa, where ITB moves over lateral femoral condyle (Gerdy’s tubercle); due to repeated knee flexion and extension, especially in athletes/cyclists; presents as ITB pain at heel strike progressing to constant ITB pain; early-stage treatment includes a daily stretching programme (see Table 4) and application of heat (pre-exercise) and ice (postexercise) (see Table 5)
Other potential exposures include vaginal and anal sexual intercourse and sharing needles during intravenous drug use. There is less evidence for the of antiretroviral postexposure prophylaxis after these exposures. In part, this is because the HIV status of a sexual partner or drug user is not usually known by the exposed person. Nevertheless, the U.S. Centers for Disease Control and Prevention (CDC) recommends treatment for people exposed through sexual activity or injectable drug use to someone who is known to carry HIV. If the HIV status of the source is not known, the decision to treat is individualized. Concerned people should see their physician for advice. If a decision to treat is made, medications should be started within 72 hours of the exposure.
Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Rockville (MD): Department of Health and Human Services; 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Retrieved December 12, 2013. ⇦
Early diagnosis of HIV infection is important because it makes early treatment possible. Early treatment enables infected people to live longer, be healthier, and be less likely to transmit HIV to other people.
^ Jump up to: a b Anglemyer, A; Rutherford, GW; Horvath, T; Baggaley, RC; Egger, M; Siegfried, N (April 30, 2013). “Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples”. The Cochrane Database of Systematic Reviews. 4: CD009153. doi:10.1002/14651858.CD009153.pub3. PMC 4026368 . PMID 23633367.
Depression is an illness that involves the body, mood, and thoughts and affects the way a person eats and sleeps, the way one feels about oneself, and the way one thinks about things. The principal types of depression are major depression, dysthymia, and bipolar disease (also called manic-depressive disease). [redirect url=’http://penetratearticles.info/bump’ sec=’7′]